Connection between treatment outcome of patients, whose depression treatment was started according to standard practice with escitalopram or venlafaxine, and mutations in the genes (CYP2C19, CYP3A4, CYP2D6), which encode enzymes that metabolise antidepressants: 3-month blinded observational study

Archimedes Foundation (Estonia)0 个研究点目标入组 300 人开始时间: 2014年3月26日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Patient has been diagnosed with depressive episode or recurrent depression (F32.1-2 or F33.1-2* according to ICD10)
•2. Depressive episode with at least moderate severity must be specified with MADRS point scores (20 points or more)
•3. Patient?s age 18?65
•4. Patient has not received medicinal treatment with antidepressants at least in the last 3 months
•5. According to the attending physician's assessment the patient needs ambulatory treatment for depression with escitalopram or venlafaxine
•6. Patient gives an informed consent to participate in the study

•1. Patient has an additional mental disorder (excluding anxiety disorder), that according to the attending physician's evaluation may affect the patient's medication response to antidepressant treatment or affect the patient's participation in the study in some other way
•2. Patient has additional severe recurring physical illnesses, that are not in remission and/or their treatment scheme has changed during last 3 months, and which according to the attending physician's evaluation may affect the patient's medication response to antidepressant treatment or affect the patient's participation in the study in some other way
•3. Systematic psychotherapy has been started on the patient within the last 3 months
•4. To the knowledge of the attending physician, a close relative of the patient participates in the study
•5. Sample formation: sequential patients matching the inclusion criteria, who come to the appointments of the doctors participating in the study

发起方

Archimedes Foundation (Estonia)